ClinicalTrials.gg
CompletedNCT04939779Updated Jun 25, 2021

Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches

A Phase 1 interventional study of LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) and LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) in Healthy, sponsored by LigaChem Biosciences, Inc.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-25.

Sponsored by LigaChem Biosciences, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

The objective of this clinical trial is to evaluate bioequivalence of "LCB01-0371 (Batch# 1650006)" and "LCB01-0371(Batch#3183817R) in healthy adult subject

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A person who is a healthy adult aged between 19 and 45 years old with the result of between 18.0 kg/m2 and 28.0 kg/m2
  2. A healthy adult whose weight is over 50 kg
  3. A person who is deemed suitable for a clinical trial subject in physical examination, vital sign tests, diagnostic examination, and 12-lead by the medical doctor, etc.

Exclusion criteria

Exclusion Criteria:

  1. A person who has a history of the disease, such as liver, kidney, gastrointestinal disease, respiratory tract disease, muscular-skeletal disease, endocrine disease, nervous system disease, blood ∙ tumor disease, cardiovascular disease, etc.
  2. A person who has a history of gastrointestinal diseases or surgery that may affect the absorption of IP, etc.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Group A

    Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)

    Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) · Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)

  • Experimental
    Group B

    Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)

    Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) · Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic evaluation: The observed maximum concentration(Cmax)

    Pharmacokinetic parameters will be assessed using non-compartmental method

    Time frame: 0-12hours

  2. Pharmacokinetic evaluation:Area under the blood concentration-time curve (AUClast)

    Area under the plasma concentration curve from zero until the last measurable concentration

    Time frame: 0-12hours

Secondary outcomes

  1. Pharmacokinetic evaluation: Time to reach Cmax(Tmax)

    Pharmacokinetic parameters will be assessed using non-compartmental method

    Time frame: 0-12hours

  2. Pharmacokinetic evaluation: Elimination half-life(t1/2)

    Pharmacokinetic parameters will be assessed using non-compartmental method

    Time frame: 0-12hours

  3. Pharmacokinetic evaluation: Apparent total body clearance after extravascular administration(CL/F)

    Pharmacokinetic parameters will be assessed using non-compartmental method

    Time frame: 0-12hours

  4. Pharmacokinetic evaluation:Apparent volume of distribution after extravascular administration(Vd/F)

    Pharmacokinetic parameters will be assessed using non-compartmental method

    Time frame: 0-12hours

  5. Pharmacokinetic evaluation:Area under the blood concentration-time curve (AUCinf)

    Area under the curve from time 0 extrapolated to infinite time

    Time frame: 0-12hours

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jan 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2021
First posted
Jun 25, 2021
StartActual
Jan 14, 2021
Primary completionActual
Jan 24, 2021
CompletionActual
Feb 1, 2021
Last update
Jun 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04939779
Lead sponsor
LigaChem Biosciences, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2021
Start date
Jan 14, 2021
Primary completion
Jan 24, 2021
Completion
Feb 1, 2021
Last update
Jun 25, 2021

Study contacts

Jae-Yong Chung
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delpazolid

Start the discussion